Tetraphase Pharmaceuticals Inc Institutional Investor Sentiment Worsened in 2018 Q1

July 27, 2018 - By Billy Entrekin

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Logo

Sentiment for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) institutional sentiment decreased to 1.05 in 2018 Q1. Its down -0.14, from 1.19 in 2017Q4. The ratio dropped, as 40 institutional investors increased or started new holdings, while 38 sold and decreased their stakes in Tetraphase Pharmaceuticals Inc. The institutional investors in our partner’s database now hold: 19.93 million shares, down from 29.51 million shares in 2017Q4. Also, the number of institutional investors holding Tetraphase Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 23 Increased: 27 New Position: 13.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $144.05 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

The stock decreased 2.79% or $0.08 during the last trading session, reaching $2.79. About 629,730 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 48.55% since July 27, 2017 and is downtrending. It has underperformed by 61.12% the S&P500.

Analysts await Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on August, 1. They expect $-0.36 earnings per share, up 56.63 % or $0.47 from last year’s $-0.83 per share. After $-0.42 actual earnings per share reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Broadfin Capital Llc holds 0.5% of its portfolio in Tetraphase Pharmaceuticals, Inc. for 1.05 million shares. 683 Capital Management Llc owns 600,000 shares or 0.16% of their US portfolio. Moreover, Tekla Capital Management Llc has 0.1% invested in the company for 859,322 shares. The Michigan-based Dow Chemical Co De has invested 0.07% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 262,896 shares.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $54,425 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Ratings analysis reveals 83% of Tetraphase Pharmaceutical’s analysts are positive. Out of 6 Wall Street analysts rating Tetraphase Pharmaceutical, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3 while the high is $11. The stock’s average target of $7.20 is 158.06% above today’s ($2.79) share price. TTPH was included in 12 notes of analysts from February 12, 2018. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by SunTrust on Wednesday, February 14. The rating was maintained by FBR Capital on Monday, June 11 with “Buy”. FBR Capital maintained the shares of TTPH in report on Tuesday, February 27 with “Buy” rating. The company was initiated on Monday, February 12 by FBR Capital. FBR Capital maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, February 21 with “Buy” rating. The company was downgraded on Wednesday, February 14 by BMO Capital Markets. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given on Wednesday, March 7 by FBR Capital. The stock has “Buy” rating by Gabelli on Thursday, March 29. The rating was maintained by FBR Capital on Monday, June 4 with “Buy”. BMO Capital Markets maintained the stock with “Market Perform” rating in Thursday, March 8 report.

More important recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Streetinsider.com which released: “Tetraphase Pharma (TTPH) Announces Positive CHMP Opinion for Xerava (eravacycline)” on July 27, 2018, also Nasdaq.com published article titled: “Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xeravaâ„¢ (eravacycline) as a Treatment for …”, Seekingalpha.com published: “Tetraphase Pharma receives positive CHMP opinion for Xerava; shares ahead 13% premarket” on July 27, 2018. More interesting news about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was released by: Nasdaq.com and their article: “Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)” with publication date: July 12, 2018.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.